ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $28.20 Average PT from Analysts

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $26.40.

SPRY has been the subject of a number of recent research reports. Leerink Partners set a $15.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday. Weiss Ratings cut shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Cantor Fitzgerald lifted their target price on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Finally, Wall Street Zen upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Bessemer Group Inc. raised its position in shares of ARS Pharmaceuticals by 3,102.1% in the 1st quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock worth $61,000 after purchasing an additional 7,290 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in ARS Pharmaceuticals during the 4th quarter valued at about $65,000. Russell Investments Group Ltd. increased its stake in ARS Pharmaceuticals by 197.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after purchasing an additional 4,427 shares in the last quarter. Alpine Woods Capital Investors LLC bought a new stake in ARS Pharmaceuticals during the 1st quarter valued at about $80,000. Finally, Syon Capital LLC bought a new stake in ARS Pharmaceuticals during the 2nd quarter valued at about $80,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting ARS Pharmaceuticals

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Positive Sentiment: Brokerage analysts maintain a consensus rating of “Moderate Buy,” suggesting some Wall Street analysts continue to see potential upside despite the recent weakness. ARS Pharmaceuticals Given Consensus Rating of Moderate Buy
• Neutral Sentiment: A reported short-interest update showed zero shares sold short both before and after the measurement period, with a zero-day days-to-cover ratio. The figures appear inconsistent or incomplete, so they provide little dependable insight into current trading sentiment.
• Negative Sentiment: Several investor-rights firms, including Rosen, Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, SBS Law, Faruqi & Faruqi and Kaplan Fox, announced or promoted the pending class action against ARS Pharmaceuticals and certain officers. The case covers investors who purchased SPRY securities from March 9 through June 24, 2026, and alleges violations of federal securities laws. SPRY Investors Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The allegations reportedly focus on whether ARS and executives—including Chief Commercial Officer Eric Karas—misled investors about the timing of expanded CVS Caremark coverage for neffy, after SPRY shares fell 23.9% in one session. Although the allegations have not been proven, the litigation could create legal costs, prolong uncertainty and weigh on investor confidence. SueWallSt ARS Pharmaceuticals Class Action Reminder

ARS Pharmaceuticals Price Performance

Shares of SPRY stock opened at $4.76 on Friday. The business’s fifty day moving average is $6.16 and its 200 day moving average is $7.74. The company has a quick ratio of 3.28, a current ratio of 3.48 and a debt-to-equity ratio of 13.72. The stock has a market cap of $473.38 million, a price-to-earnings ratio of -2.18 and a beta of 1.05. ARS Pharmaceuticals has a twelve month low of $4.73 and a twelve month high of $13.15.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.15). The firm had revenue of $33.66 million for the quarter, compared to analysts’ expectations of $31.32 million. ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. Research analysts expect that ARS Pharmaceuticals will post -1.9 EPS for the current fiscal year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.